Fischer M, Goldschmitt J, Peschel C, Brakenhoff J P, Kallen K J, Wollmer A, Grötzinger J, Rose-John S
Department of Medicine-Section-Pathophysiology, Mainz University, Germany.
Nat Biotechnol. 1997 Feb;15(2):142-5. doi: 10.1038/nbt0297-142.
Efficient expansion of hematopoietic progenitor cells requires, at least, the simultaneous stimulation of the receptors c-kit and gp130. While c-kit is activated by SCF; gp130, in cells which do not express sufficient amounts of IL-6R, can be activated by the complex of soluble IL-6R (sIL-6R) and IL-6. The therapeutic use of IL-6/sIL-6R, however, has been hampered by the high concentrations of the sIL-6R protein required. We have designed a fusion protein of sIL-6R and IL-6, linked by a flexible peptide chain, that was expressed to high levels. On gp130 expressing cells the fusion protein turned out to be fully active at 100 to 1,000-fold lower concentration than the combination of unlinked IL-6 and IL-6R. The fusion protein was used to effectively expand human hematopoietic progenitor cells ex vivo in a dose dependent fashion.
造血祖细胞的有效扩增至少需要同时刺激c-kit和gp130受体。c-kit由干细胞因子(SCF)激活;而在未表达足够量白细胞介素-6受体(IL-6R)的细胞中,gp130可被可溶性IL-6R(sIL-6R)与IL-6的复合物激活。然而,IL-6/sIL-6R的治疗应用受到所需sIL-6R蛋白高浓度的阻碍。我们设计了一种由柔性肽链连接的sIL-6R与IL-6的融合蛋白,其表达水平很高。在表达gp130的细胞上,该融合蛋白在比未连接的IL-6和IL-6R组合低100至1000倍的浓度下就表现出完全活性。该融合蛋白被用于以剂量依赖方式在体外有效扩增人造血祖细胞。